Alpine Immune Sciences ( NASDAQ:ALPN – Get Free Report ) ‘s stock had its 'outperform' rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $19.00 price objective on the biotechnology company's stock. Wedbush's price target indicates a potential upside of 47.29% from the company's previous close. Separately, HC Wainwright reiterated a 'buy' rating and set a $17.00 price target on shares of Alpine Immune Sciences in a report on Thursday.

https://www.dailypolitical.com/2023/09/02/alpine-immune-sciences-nasdaqalpn-stock-rating-reaffirmed-by-wedbush.html

#dailypolitical